HN22C0009

Phase I clinical study of innovative CD19-targeted CAR-T

AbClon Inc.

Innovative Therapeutic Antibody AbClon

ONCOLOGY | **Phase 1**

Product Type	Autologous CAR-T (chimeric antigen receptor-T) cell therapy
Indication	Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Target	CD19
MoA(Mechanism of Action)	AT101 binding to CD19-expressed cancer cells → Activation of the intracellular stimulatory and costimulatory domain in CAR → Downstream signaling cascades → Secretion of inflammatory cytokines and exocytosis of cytotoxic granules → Killing of NHL cancer cells
Competitiveness	• Proprietary CD19-targeting humanized antibody (scFv) - Unique antibody (h1218) different from the previously approved CD19-targeted CAR-T products that are based on murine-derived FMC63 antibody - Lower immunogenicity and higher CAR-T cell persistency through humanization - Exclusive IP rights • Different epitope: new opportunity to patients • Automated and closed manufacturing process: Improved efficiency and quality
Development Stage	Phase 1
Route of Administration	IV infusion

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund